• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于 PLCO 和 SELECT 试验预测任何及更高等级前列腺癌的未来风险。

Prediction of future risk of any and higher-grade prostate cancer based on the PLCO and SELECT trials.

机构信息

Department of Population Health Sciences, Mail Code 7933, 7703 Floyd Curl Drive, San Antonio, TX, 78229-3900, USA.

Department of Biostatistics, University of North Carolina, Chapel Hill, NC, USA.

出版信息

BMC Urol. 2022 Mar 26;22(1):45. doi: 10.1186/s12894-022-00986-w.

DOI:10.1186/s12894-022-00986-w
PMID:35351104
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8966358/
Abstract

BACKGROUND

A model was built that characterized effects of individual factors on five-year prostate cancer (PCa) risk in the Prostate, Lung, Colon, and Ovarian Cancer Screening Trial (PLCO) and the Selenium and Vitamin E Cancer Prevention Trial (SELECT). This model was validated in a third San Antonio Biomarkers of Risk (SABOR) screening cohort.

METHODS

A prediction model for 1- to 5-year risk of developing PCa and Gleason > 7 PCa (HG PCa) was built on PLCO and SELECT using the Cox proportional hazards model adjusting for patient baseline characteristics. Random forests and neural networks were compared to Cox proportional hazard survival models, using the trial datasets for model building and the SABOR cohort for model evaluation. The most accurate prediction model is included in an online calculator.

RESULTS

The respective rates of PCa were 8.9%, 7.2%, and 11.1% in PLCO (n = 31,495), SELECT (n = 35,507), and SABOR (n = 1790) over median follow-up of 11.7, 8.1 and 9.0 years. The Cox model showed higher prostate-specific antigen (PSA), BMI and age, and African American race to be associated with PCa and HGPCa. Five-year risk predictions from the combined SELECT and PLCO model effectively discriminated risk in the SABOR cohort with C-index 0.76 (95% CI [0.72, 0.79]) for PCa, and 0.74 (95% CI [0.65,0.83]) for HGPCa.

CONCLUSIONS

A 1- to 5-year PCa risk prediction model developed from PLCO and SELECT was validated with SABOR and implemented online. This model can individualize and inform shared screening decisions.

摘要

背景

建立了一个模型,该模型描述了个体因素对前列腺癌(PCa)筛查试验(PLCO)和硒和维生素 E 癌症预防试验(SELECT)中五年 PCa 风险的影响。该模型在第三个圣安东尼奥风险生物标志物(SABOR)筛查队列中进行了验证。

方法

使用 Cox 比例风险模型,根据患者基线特征调整,在 PLCO 和 SELECT 中建立了用于预测 1 至 5 年内发生 PCa 和 Gleason > 7 PCa(HG PCa)风险的预测模型。随机森林和神经网络与 Cox 比例风险生存模型进行了比较,使用试验数据集进行模型构建,使用 SABOR 队列进行模型评估。最准确的预测模型包含在在线计算器中。

结果

在 PLCO(n = 31495)、SELECT(n = 35507)和 SABOR(n = 1790)中,中位随访 11.7、8.1 和 9.0 年,PCa 的发生率分别为 8.9%、7.2%和 11.1%。Cox 模型显示较高的前列腺特异性抗原(PSA)、BMI 和年龄以及非裔美国人种族与 PCa 和 HGPCa 相关。来自 SELECT 和 PLCO 联合模型的五年风险预测有效地在 SABOR 队列中区分了风险,PCa 的 C 指数为 0.76(95%CI [0.72, 0.79]),HGPCa 为 0.74(95%CI [0.65,0.83])。

结论

从 PLCO 和 SELECT 开发的 1 至 5 年 PCa 风险预测模型在 SABOR 中进行了验证,并在线实施。该模型可以对个体进行分类,并为共享筛查决策提供信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d339/8966358/62978022fa55/12894_2022_986_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d339/8966358/301919e00c1e/12894_2022_986_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d339/8966358/5d6f3fc23bd5/12894_2022_986_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d339/8966358/6fa82566b9be/12894_2022_986_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d339/8966358/62978022fa55/12894_2022_986_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d339/8966358/301919e00c1e/12894_2022_986_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d339/8966358/5d6f3fc23bd5/12894_2022_986_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d339/8966358/6fa82566b9be/12894_2022_986_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d339/8966358/62978022fa55/12894_2022_986_Fig4_HTML.jpg

相似文献

1
Prediction of future risk of any and higher-grade prostate cancer based on the PLCO and SELECT trials.基于 PLCO 和 SELECT 试验预测任何及更高等级前列腺癌的未来风险。
BMC Urol. 2022 Mar 26;22(1):45. doi: 10.1186/s12894-022-00986-w.
2
3
The use of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican referral population: a validation study.非那雄胺调整后的前列腺癌预防试验前列腺癌风险计算器在墨西哥转诊人群中的应用:一项验证研究。
Urol Int. 2012;89(1):9-16. doi: 10.1159/000338270. Epub 2012 May 24.
4
Risk-stratified multi-round PSA screening for prostate cancer integrating the screening reference level and subgroup-specific progression indicators.基于筛查参考水平和亚组特异性进展指标的前列腺癌风险分层多轮 PSA 筛查。
Eur J Med Res. 2023 Jul 26;28(1):257. doi: 10.1186/s40001-023-01228-x.
5
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.调和欧洲随机前列腺癌筛查研究(ERSPC)和前列腺、肺癌、结直肠癌和卵巢癌筛查试验(PLCO)中筛查对前列腺癌死亡率的影响。
Ann Intern Med. 2017 Oct 3;167(7):449-455. doi: 10.7326/M16-2586. Epub 2017 Sep 5.
6
Prostate Cancer Incidence and Mortality Following a Negative Biopsy in a Population Undergoing PSA Screening.在接受 PSA 筛查的人群中,前列腺癌的发病率和死亡率在阴性活检后。
Urology. 2021 Sep;155:62-69. doi: 10.1016/j.urology.2021.05.060. Epub 2021 Jun 26.
7
Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.55 岁至 60 岁患者中基线前列腺特异性抗原水平与长期临床显著前列腺癌诊断的相关性:前列腺、肺、结直肠和卵巢(PLCO)癌症筛查试验队列的二次分析。
JAMA Netw Open. 2020 Jan 3;3(1):e1919284. doi: 10.1001/jamanetworkopen.2019.19284.
8
Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).美国非裔美国男性和非西班牙裔白种男性中硒和维生素 E 癌症预防试验(SELECT)中肥胖与前列腺癌风险之间的关联存在差异。
JAMA Oncol. 2015 Jun;1(3):342-9. doi: 10.1001/jamaoncol.2015.0513.
9
European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study.欧洲前列腺癌筛查随机研究(ERSPC)风险计算器在预测前列腺癌方面显著优于前列腺癌预防试验(PCPT)2.0:一项多机构研究。
BJU Int. 2016 Nov;118(5):706-713. doi: 10.1111/bju.13437. Epub 2016 Feb 29.
10
Higher baseline dietary fat and fatty acid intake is associated with increased risk of incident prostate cancer in the SABOR study.更高的基础膳食脂肪和脂肪酸摄入量与 SABOR 研究中前列腺癌发病风险增加相关。
Prostate Cancer Prostatic Dis. 2019 May;22(2):244-251. doi: 10.1038/s41391-018-0105-2. Epub 2018 Nov 1.

引用本文的文献

1
Advancing prostate cancer detection: a comparative analysis of PCLDA-SVM and PCLDA-KNN classifiers for enhanced diagnostic accuracy.推进前列腺癌检测:PCLDA-SVM 和 PCLDA-KNN 分类器的比较分析,以提高诊断准确性。
Sci Rep. 2023 Aug 23;13(1):13745. doi: 10.1038/s41598-023-40906-y.

本文引用的文献

1
Lifetime Benefits and Harms of Prostate-Specific Antigen-Based Risk-Stratified Screening for Prostate Cancer.基于前列腺特异性抗原的风险分层前列腺癌筛查的终生获益和危害。
J Natl Cancer Inst. 2020 Oct 1;112(10):1013-1020. doi: 10.1093/jnci/djaa001.
2
Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.经直肠超声引导前列腺活检与多参数前列腺磁共振成像引导活检在前列腺特异性抗原升高的初次活检男性中的头对头比较:一项大型前瞻性多中心临床研究。
Eur Urol. 2019 Apr;75(4):570-578. doi: 10.1016/j.eururo.2018.11.023. Epub 2018 Nov 23.
3
DeepSurv: personalized treatment recommender system using a Cox proportional hazards deep neural network.DeepSurv:使用 Cox 比例风险深度神经网络的个性化治疗推荐系统。
BMC Med Res Methodol. 2018 Feb 26;18(1):24. doi: 10.1186/s12874-018-0482-1.
4
Impact of numeracy on understanding of prostate cancer risk reduction in PSA screening.算术能力对前列腺特异性抗原筛查中前列腺癌风险降低理解的影响。
PLoS One. 2017 Dec 28;12(12):e0190357. doi: 10.1371/journal.pone.0190357. eCollection 2017.
5
The US Preventive Services Task Force 2017 Draft Recommendation Statement on Screening for Prostate Cancer: An Invitation to Review and Comment.美国预防服务工作组2017年关于前列腺癌筛查的建议声明草案:邀请审查与评论。
JAMA. 2017 May 16;317(19):1949-1950. doi: 10.1001/jama.2017.4413.
6
Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.通过纳入 2014 年国际泌尿病理学会格里森分级和筛状生长,改进用于初始前列腺活检的 Rotterdam 欧洲前列腺癌筛查风险计算器。
Eur Urol. 2017 Jul;72(1):45-51. doi: 10.1016/j.eururo.2017.01.033. Epub 2017 Feb 2.
7
Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men.数字直肠检查与血清前列腺特异性抗原在前列腺癌早期检测中的比较:6630 例男性多中心临床试验结果。
J Urol. 2017 Feb;197(2S):S200-S207. doi: 10.1016/j.juro.2016.10.073. Epub 2016 Dec 22.
8
Prostate Cancer Incidence Rates 2 Years After the US Preventive Services Task Force Recommendations Against Screening.美国预防服务工作组建议停止筛查后两年的前列腺癌发病率
JAMA Oncol. 2016 Dec 1;2(12):1657-1660. doi: 10.1001/jamaoncol.2016.2667.
9
Reevaluating PSA Testing Rates in the PLCO Trial.重新评估前列腺、肺、结直肠癌和卵巢癌筛查试验(PLCO)中的前列腺特异性抗原(PSA)检测率
N Engl J Med. 2016 May 5;374(18):1795-6. doi: 10.1056/NEJMc1515131.
10
The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening.纪念斯隆凯特琳癌症中心关于前列腺癌筛查的建议。
Urology. 2016 May;91:12-8. doi: 10.1016/j.urology.2015.12.054. Epub 2016 Feb 2.